Recent News

• 01.30.2026 - Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
• 01.06.2026 - Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
• 12.29.2025 - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
• 12.29.2025 - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
• 12.29.2025 - Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
• 12.29.2025 - Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
• 12.16.2025 - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
• 12.09.2025 - Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
• 11.24.2025 - Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Recent Filings

• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.31.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.29.2025 - 8-K Current report
• 12.29.2025 - 8-K Current report
• 12.29.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.16.2025 - 8-K Current report
• 12.09.2025 - EX-99.1 EX-99.1
• 12.09.2025 - 8-K Current report
• 11.24.2025 - 8-K Current report
• 11.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]